AdvanCell Establishes U.S. Headquarters and Manufacturing Hub in Greater Boston
AdvanCell has established its U.S. Global Headquarters in the Greater Boston area and leased a 128,000-square-foot facility that will serve as its flagship U.S. manufacturing center, a move that expands the clinical-stage radiopharmaceutical company’s North American footprint and supports its long-term commercialization strategy.
The new facility, located at IQHQ’s Innovation Park campus in Andover, Massachusetts, will house both corporate operations and advanced manufacturing capabilities as AdvanCell continues to develop targeted alpha therapies for cancer. The investment marks a significant milestone in the company’s transition toward becoming a U.S.-based radiopharmaceutical organization with integrated operations spanning North America and Australia.
The expansion is designed to support the continued development of ADVC001, the company’s lead prostate cancer program, as well as its broader Lead-212 targeted alpha therapy pipeline. AdvanCell said the Andover site will become its first internal manufacturing facility in the United States, providing infrastructure to support future clinical and commercial production requirements.
“Establishing AdvanCell’s U.S. Global Headquarters and future manufacturing facility reinforces our commitment to U.S. expansion and represents an important milestone in AdvanCell’s strategy to build a global, vertically integrated targeted alpha therapy company,” said Chief Executive Officer Philina Lee, Ph.D.
Lee said the facility will play a central role in scaling production capabilities as the company advances ADVC001 and additional Lead-212 programs through clinical development. She noted that AdvanCell will continue to leverage its Australian operations for clinical translation, isotope supply and manufacturing process innovation while expanding its U.S. presence.
The Greater Boston region has become a major hub for biotechnology and radiopharmaceutical development, offering access to research institutions, manufacturing expertise, specialized talent and a deep life sciences ecosystem. By locating its headquarters and manufacturing operations in the area, AdvanCell gains proximity to key industry partners and resources needed to support future growth.
In addition to the Andover buildout, the company is working with a contract development and manufacturing organization to establish U.S.-based drug product manufacturing capabilities. AdvanCell said the dual-track strategy is expected to accelerate access to manufacturing capacity while the new facility is fitted out and qualified for production.
The approach is intended to support ongoing clinical development, including Phase 2 enrollment in the company’s TheraPb study in the United States, while creating the foundation for future Phase 3 and commercial-scale manufacturing operations.
AdvanCell’s lead candidate, 212Pb-ADVC001, is a prostate-specific membrane antigen (PSMA)-targeting radioligand designed for the treatment of prostate cancer. The therapy uses Lead-212, an alpha-emitting radionuclide with a 10.6-hour half-life, to deliver targeted radiation directly to cancer cells while limiting exposure to surrounding healthy tissue.
The ongoing TheraPb trial is a Phase 1/2 study evaluating ADVC001 in patients with metastatic prostate cancer. Following completion of the Phase 1b dose-escalation portion of the trial, the Phase 2 expansion stage is evaluating efficacy and safety across two dose levels. The study includes patients with PSMA-positive metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer.
Radiopharmaceutical development has emerged as one of the fastest-growing segments within oncology, driving increased investment in manufacturing infrastructure as companies seek to secure isotope supply chains and production capacity. Because radiopharmaceuticals have short shelf lives and complex production requirements, manufacturing scale and geographic reach are increasingly viewed as critical components of commercialization readiness.
For AdvanCell, the establishment of a U.S. headquarters and large-scale manufacturing facility represents a strategic investment in both operational infrastructure and future market access as it advances its targeted alpha therapy platform toward later-stage development and potential commercialization.
